Share Price and Basic Stock Data
Last Updated: January 19, 2026, 8:22 pm
| PEG Ratio | 6.36 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Apollo Hospitals Enterprise Ltd operates in the Hospitals & Medical Services industry and has reported a market capitalization of ₹1,04,998 Cr. The company’s stock price stood at ₹7,302. Apollo Hospitals demonstrated a consistent upward trajectory in sales, recording ₹16,612 Cr in revenue for the fiscal year ending March 2023, which rose to ₹19,059 Cr for March 2024, and further to ₹21,794 Cr for March 2025. The trailing twelve months (TTM) revenue reached ₹23,265 Cr, indicating strong growth momentum. Quarterly sales figures also reflect this trend, with sales increasing from ₹4,251 Cr in September 2022 to ₹4,847 Cr by September 2023. This growth can be attributed to heightened demand for healthcare services post-pandemic and strategic expansions in their service offerings. The operating profit margin (OPM) has shown stability, averaging around 13% for the last few quarters and reaching 15% in September 2024, highlighting effective cost management alongside revenue growth.
Profitability and Efficiency Metrics
The profitability of Apollo Hospitals is underscored by its net profit, which recorded ₹1,729 Cr for the TTM, a substantial recovery from ₹844 Cr in March 2023. The net profit margin improved to 6.75% in March 2025, up from 5.34% in March 2023, demonstrating enhanced operational efficiency. Return on equity (ROE) stood at 18.4%, while return on capital employed (ROCE) was reported at 16.6%, suggesting that the company effectively utilizes its equity and capital to generate profits. The interest coverage ratio (ICR) of 7.03x signifies strong financial health, enabling the company to comfortably meet its interest obligations. However, the cash conversion cycle (CCC) improved to -6 days, indicating a robust operational cycle that allows Apollo to convert its investments into cash efficiently. These metrics reflect a compelling profitability profile, positioning Apollo Hospitals favorably against typical sector performance.
Balance Sheet Strength and Financial Ratios
Apollo Hospitals has reported reserves of ₹9,021 Cr against borrowings of ₹7,987 Cr, showcasing a healthy balance sheet with a total liabilities figure of ₹21,950 Cr as of September 2025. The company’s total assets reached ₹21,950 Cr, indicating a solid asset base to support its operations. The current ratio stood at 1.53, reflecting adequate liquidity to meet short-term obligations, while the quick ratio of 1.43 further suggests a strong liquidity position. The debt-to-equity ratio was recorded at 0.64, which is within a manageable range, indicating that the company is not overly reliant on debt for financing its operations. Additionally, the book value per share increased to ₹571.09 as of March 2025, illustrating a growing equity base. This financial stability is critical for sustaining growth and navigating potential market challenges.
Shareholding Pattern and Investor Confidence
Apollo Hospitals’ shareholding pattern reveals a diversified ownership structure, with promoters holding 28.02%, foreign institutional investors (FIIs) at 44.20%, domestic institutional investors (DIIs) at 21.12%, and the public holding 6.43%. The steady presence of FIIs, which peaked at 47.94% in December 2022 before stabilizing, indicates strong investor confidence in the company’s growth prospects. The number of shareholders increased to 1,60,556 by September 2025, reflecting growing interest among retail investors. However, the slight decline in promoter holding from 29.33% in March 2023 to 28.02% could raise concerns about insider confidence. The stability of DIIs around the 21% mark suggests institutional backing, which is often a positive signal for prospective investors. Overall, the shareholding dynamics present a favorable outlook for the company.
Outlook, Risks, and Final Insight
The outlook for Apollo Hospitals appears promising, driven by robust revenue growth and improving profitability metrics. However, risks such as increasing competition in the healthcare sector, rising operational costs, and potential regulatory changes must be considered. The company’s ability to maintain its operating margins amid these challenges will be critical. Furthermore, while the strong institutional support and growing retail interest bolster confidence, any significant dip in promoter holdings could influence market perceptions negatively. In scenarios where Apollo continues to innovate and expand its service offerings, it could solidify its market position and enhance shareholder value. Conversely, if operational costs escalate or competition intensifies without adequate strategic responses, profitability could be adversely affected, necessitating vigilant management to navigate these dynamics effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.6 Cr. | 136 | 187/120 | 9.31 | 117 | 2.57 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 23.3 Cr. | 22.2 | 33.8/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.8 Cr. | 10.5 | 20.5/7.08 | 121 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 108 Cr. | 57.7 | 98.7/55.2 | 23.9 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.4 Cr. | 3.60 | 6.94/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 25,618.36 Cr | 683.18 | 89.84 | 93.18 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,251 | 4,264 | 4,302 | 4,418 | 4,847 | 4,851 | 4,944 | 5,086 | 5,589 | 5,527 | 5,592 | 5,842 | 6,304 |
| Expenses | 3,699 | 3,780 | 3,814 | 3,909 | 4,219 | 4,237 | 4,303 | 4,410 | 4,774 | 4,765 | 4,822 | 4,990 | 5,362 |
| Operating Profit | 552 | 484 | 488 | 509 | 628 | 614 | 640 | 675 | 816 | 762 | 770 | 852 | 941 |
| OPM % | 13% | 11% | 11% | 12% | 13% | 13% | 13% | 13% | 15% | 14% | 14% | 15% | 15% |
| Other Income | 23 | 35 | 20 | 34 | 26 | 29 | 37 | 49 | 44 | 69 | 72 | 54 | 61 |
| Interest | 93 | 100 | 95 | 106 | 111 | 113 | 119 | 116 | 118 | 110 | 115 | 108 | 110 |
| Depreciation | 155 | 153 | 159 | 167 | 163 | 167 | 190 | 177 | 184 | 185 | 211 | 215 | 218 |
| Profit before tax | 327 | 266 | 254 | 270 | 379 | 363 | 368 | 430 | 557 | 536 | 516 | 583 | 675 |
| Tax % | 35% | 39% | 43% | 36% | 34% | 30% | 30% | 27% | 29% | 29% | 20% | 24% | 27% |
| Net Profit | 213 | 162 | 146 | 173 | 249 | 254 | 258 | 316 | 396 | 379 | 414 | 441 | 494 |
| EPS in Rs | 14.19 | 10.68 | 10.05 | 11.59 | 16.20 | 17.06 | 17.65 | 21.23 | 26.34 | 25.89 | 27.10 | 30.10 | 33.19 |
Last Updated: January 2, 2026, 11:30 am
Below is a detailed analysis of the quarterly data for Apollo Hospitals Enterprise Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 6,304.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,842.00 Cr. (Jun 2025) to 6,304.00 Cr., marking an increase of 462.00 Cr..
- For Expenses, as of Sep 2025, the value is 5,362.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,990.00 Cr. (Jun 2025) to 5,362.00 Cr., marking an increase of 372.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 941.00 Cr.. The value appears strong and on an upward trend. It has increased from 852.00 Cr. (Jun 2025) to 941.00 Cr., marking an increase of 89.00 Cr..
- For OPM %, as of Sep 2025, the value is 15.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 15.00%.
- For Other Income, as of Sep 2025, the value is 61.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Jun 2025) to 61.00 Cr., marking an increase of 7.00 Cr..
- For Interest, as of Sep 2025, the value is 110.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 108.00 Cr. (Jun 2025) to 110.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Sep 2025, the value is 218.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 215.00 Cr. (Jun 2025) to 218.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 675.00 Cr.. The value appears strong and on an upward trend. It has increased from 583.00 Cr. (Jun 2025) to 675.00 Cr., marking an increase of 92.00 Cr..
- For Tax %, as of Sep 2025, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Jun 2025) to 27.00%, marking an increase of 3.00%.
- For Net Profit, as of Sep 2025, the value is 494.00 Cr.. The value appears strong and on an upward trend. It has increased from 441.00 Cr. (Jun 2025) to 494.00 Cr., marking an increase of 53.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 33.19. The value appears strong and on an upward trend. It has increased from 30.10 (Jun 2025) to 33.19, marking an increase of 3.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:39 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,357 | 5,129 | 6,150 | 7,256 | 8,243 | 9,617 | 11,247 | 10,560 | 14,663 | 16,612 | 19,059 | 21,794 | 23,265 |
| Expenses | 3,681 | 4,392 | 5,465 | 6,522 | 7,442 | 8,548 | 9,656 | 9,420 | 12,474 | 14,548 | 16,665 | 18,761 | 19,940 |
| Operating Profit | 676 | 737 | 684 | 734 | 801 | 1,070 | 1,591 | 1,140 | 2,189 | 2,065 | 2,394 | 3,033 | 3,324 |
| OPM % | 16% | 14% | 11% | 10% | 10% | 11% | 14% | 11% | 15% | 12% | 13% | 14% | 14% |
| Other Income | 18 | 47 | 92 | 60 | 24 | 26 | 222 | 103 | 368 | 75 | 123 | 222 | 256 |
| Interest | 119 | 118 | 180 | 257 | 295 | 327 | 533 | 449 | 379 | 381 | 449 | 458 | 442 |
| Depreciation | 168 | 212 | 264 | 314 | 359 | 396 | 620 | 573 | 601 | 615 | 687 | 758 | 828 |
| Profit before tax | 407 | 455 | 332 | 222 | 171 | 373 | 660 | 221 | 1,578 | 1,144 | 1,380 | 2,039 | 2,309 |
| Tax % | 25% | 29% | 29% | 41% | 65% | 47% | 34% | 38% | 30% | 22% | 32% | 26% | |
| Net Profit | 315 | 335 | 235 | 131 | 60 | 200 | 432 | 137 | 1,108 | 844 | 935 | 1,505 | 1,729 |
| EPS in Rs | 22.77 | 24.43 | 16.99 | 15.88 | 8.44 | 16.96 | 32.70 | 10.46 | 73.42 | 56.97 | 62.50 | 100.56 | 116.28 |
| Dividend Payout % | 25% | 24% | 35% | 38% | 59% | 35% | 18% | 29% | 16% | 26% | 26% | 13% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 6.35% | -29.85% | -44.26% | -54.20% | 233.33% | 116.00% | -68.29% | 708.76% | -23.83% | 10.78% | 60.96% |
| Change in YoY Net Profit Growth (%) | 0.00% | -36.20% | -14.40% | -9.94% | 287.53% | -117.33% | -184.29% | 777.05% | -732.59% | 34.61% | 50.18% |
Apollo Hospitals Enterprise Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 14% |
| 3 Years: | 14% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 34% |
| 3 Years: | 18% |
| TTM: | 52% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 37% |
| 3 Years: | 23% |
| 1 Year: | 14% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 15% |
| Last Year: | 18% |
Last Updated: September 4, 2025, 11:25 pm
Balance Sheet
Last Updated: December 4, 2025, 12:57 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 70 | 70 | 70 | 70 | 70 | 70 | 70 | 72 | 72 | 72 | 72 | 72 | 72 |
| Reserves | 2,907 | 3,102 | 3,262 | 3,244 | 3,182 | 3,264 | 3,270 | 4,531 | 5,551 | 6,126 | 6,864 | 8,140 | 9,021 |
| Borrowings | 1,344 | 1,992 | 2,834 | 3,125 | 3,427 | 3,673 | 3,596 | 4,160 | 4,068 | 4,332 | 5,333 | 7,864 | 7,987 |
| Other Liabilities | 1,029 | 1,296 | 1,195 | 1,665 | 1,917 | 2,159 | 4,354 | 2,629 | 3,570 | 3,886 | 4,474 | 4,568 | 4,870 |
| Total Liabilities | 5,350 | 6,459 | 7,360 | 8,103 | 8,596 | 9,166 | 11,289 | 11,392 | 13,261 | 14,416 | 16,742 | 20,644 | 21,950 |
| Fixed Assets | 2,681 | 3,244 | 3,997 | 4,591 | 4,773 | 4,982 | 7,432 | 6,778 | 8,296 | 8,520 | 9,664 | 10,988 | 11,262 |
| CWIP | 491 | 533 | 562 | 347 | 712 | 822 | 236 | 234 | 46 | 610 | 873 | 921 | 1,026 |
| Investments | 322 | 311 | 352 | 406 | 352 | 462 | 434 | 1,343 | 816 | 574 | 986 | 2,487 | 3,008 |
| Other Assets | 1,855 | 2,372 | 2,448 | 2,759 | 2,759 | 2,901 | 3,187 | 3,037 | 4,104 | 4,712 | 5,219 | 6,248 | 6,653 |
| Total Assets | 5,350 | 6,459 | 7,360 | 8,103 | 8,596 | 9,166 | 11,289 | 11,392 | 13,261 | 14,416 | 16,742 | 20,644 | 21,950 |
Below is a detailed analysis of the balance sheet data for Apollo Hospitals Enterprise Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 72.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 72.00 Cr..
- For Reserves, as of Sep 2025, the value is 9,021.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,140.00 Cr. (Mar 2025) to 9,021.00 Cr., marking an increase of 881.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7,987.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 7,864.00 Cr. (Mar 2025) to 7,987.00 Cr., marking an increase of 123.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4,870.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,568.00 Cr. (Mar 2025) to 4,870.00 Cr., marking an increase of 302.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 21,950.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20,644.00 Cr. (Mar 2025) to 21,950.00 Cr., marking an increase of 1,306.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11,262.00 Cr.. The value appears strong and on an upward trend. It has increased from 10,988.00 Cr. (Mar 2025) to 11,262.00 Cr., marking an increase of 274.00 Cr..
- For CWIP, as of Sep 2025, the value is 1,026.00 Cr.. The value appears strong and on an upward trend. It has increased from 921.00 Cr. (Mar 2025) to 1,026.00 Cr., marking an increase of 105.00 Cr..
- For Investments, as of Sep 2025, the value is 3,008.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,487.00 Cr. (Mar 2025) to 3,008.00 Cr., marking an increase of 521.00 Cr..
- For Other Assets, as of Sep 2025, the value is 6,653.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,248.00 Cr. (Mar 2025) to 6,653.00 Cr., marking an increase of 405.00 Cr..
- For Total Assets, as of Sep 2025, the value is 21,950.00 Cr.. The value appears strong and on an upward trend. It has increased from 20,644.00 Cr. (Mar 2025) to 21,950.00 Cr., marking an increase of 1,306.00 Cr..
Notably, the Reserves (9,021.00 Cr.) exceed the Borrowings (7,987.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 675.00 | 736.00 | 682.00 | 731.00 | 798.00 | -2.00 | -2.00 | -3.00 | -2.00 | -2.00 | -3.00 | -4.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44 | 43 | 36 | 38 | 37 | 39 | 33 | 46 | 44 | 49 | 48 | 51 |
| Inventory Days | 47 | 50 | 49 | 47 | 51 | 46 | 49 | 16 | 21 | 17 | 17 | 16 |
| Days Payable | 55 | 59 | 66 | 51 | 55 | 56 | 60 | 74 | 79 | 82 | 88 | 72 |
| Cash Conversion Cycle | 36 | 34 | 19 | 34 | 33 | 29 | 22 | -12 | -14 | -16 | -23 | -6 |
| Working Capital Days | 23 | 24 | 16 | 27 | 8 | -3 | -8 | -4 | 5 | -1 | -19 | -6 |
| ROCE % | 12% | 12% | 9% | 8% | 7% | 10% | 14% | 8% | 17% | 14% | 15% | 17% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Axis Large Cap Fund | 919,526 | 1.98 | 674.52 | 988,647 | 2025-12-15 01:19:34 | -6.99% |
| Mirae Asset Large Cap Fund | 777,300 | 1.36 | 570.19 | 682,517 | 2025-12-15 01:19:34 | 13.89% |
| Invesco India Contra Fund | 711,861 | 2.54 | 522.19 | N/A | N/A | N/A |
| Axis Focused Fund | 668,123 | 3.94 | 490.1 | N/A | N/A | N/A |
| HDFC Flexi Cap Fund | 650,000 | 0.51 | 476.81 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 648,795 | 5.63 | 475.92 | 648,795 | 2025-04-22 17:25:42 | 0% |
| Franklin India Flexi Cap Fund | 591,846 | 2.17 | 434.15 | N/A | N/A | N/A |
| Mirae Asset ELSS Tax Saver Fund | 558,951 | 1.5 | 410.02 | N/A | N/A | N/A |
| Mirae Asset Large & Midcap Fund | 538,597 | 0.91 | 395.09 | 488,597 | 2025-12-15 01:19:34 | 10.23% |
| Axis ELSS Tax Saver Fund | 493,873 | 1.03 | 362.28 | 1,426,357 | 2025-12-08 03:52:34 | -65.38% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 100.56 | 62.50 | 56.97 | 73.42 | 10.74 |
| Diluted EPS (Rs.) | 100.56 | 62.50 | 56.97 | 73.42 | 10.74 |
| Cash EPS (Rs.) | 155.05 | 111.54 | 104.51 | 118.34 | 49.31 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 571.09 | 509.07 | 454.19 | 408.74 | 333.96 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 571.09 | 509.07 | 454.19 | 408.74 | 333.96 |
| Revenue From Operations / Share (Rs.) | 1515.58 | 1325.40 | 1155.25 | 1019.65 | 734.35 |
| PBDIT / Share (Rs.) | 224.07 | 173.64 | 148.81 | 157.39 | 82.22 |
| PBIT / Share (Rs.) | 171.39 | 125.87 | 106.02 | 115.62 | 42.37 |
| PBT / Share (Rs.) | 139.51 | 94.75 | 79.53 | 109.74 | 15.35 |
| Net Profit / Share (Rs.) | 102.37 | 63.77 | 61.72 | 76.57 | 9.46 |
| NP After MI And SOA / Share (Rs.) | 100.55 | 62.49 | 56.96 | 73.41 | 10.46 |
| PBDIT Margin (%) | 14.78 | 13.10 | 12.88 | 15.43 | 11.19 |
| PBIT Margin (%) | 11.30 | 9.49 | 9.17 | 11.33 | 5.76 |
| PBT Margin (%) | 9.20 | 7.14 | 6.88 | 10.76 | 2.08 |
| Net Profit Margin (%) | 6.75 | 4.81 | 5.34 | 7.50 | 1.28 |
| NP After MI And SOA Margin (%) | 6.63 | 4.71 | 4.93 | 7.19 | 1.42 |
| Return on Networth / Equity (%) | 17.60 | 12.95 | 13.21 | 18.77 | 3.26 |
| Return on Capital Employeed (%) | 15.32 | 14.97 | 13.73 | 15.38 | 6.49 |
| Return On Assets (%) | 6.99 | 5.36 | 5.67 | 8.00 | 1.31 |
| Long Term Debt / Equity (X) | 0.53 | 0.32 | 0.31 | 0.43 | 0.53 |
| Total Debt / Equity (X) | 0.64 | 0.45 | 0.43 | 0.46 | 0.54 |
| Asset Turnover Ratio (%) | 1.17 | 1.22 | 0.54 | 0.55 | 0.86 |
| Current Ratio (X) | 1.53 | 1.13 | 1.30 | 1.73 | 1.79 |
| Quick Ratio (X) | 1.43 | 1.03 | 1.19 | 1.55 | 1.66 |
| Inventory Turnover Ratio (X) | 46.34 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 18.89 | 24.00 | 31.15 | 4.13 | 25.46 |
| Dividend Payout Ratio (CP) (%) | 12.39 | 13.60 | 17.79 | 2.63 | 5.29 |
| Earning Retention Ratio (%) | 81.11 | 76.00 | 68.85 | 95.87 | 74.54 |
| Cash Earning Retention Ratio (%) | 87.61 | 86.40 | 82.21 | 97.37 | 94.71 |
| Interest Coverage Ratio (X) | 7.03 | 5.56 | 5.62 | 5.98 | 2.63 |
| Interest Coverage Ratio (Post Tax) (X) | 4.21 | 3.04 | 3.33 | 3.13 | 1.17 |
| Enterprise Value (Cr.) | 99584.27 | 93953.52 | 64237.57 | 66797.88 | 43713.80 |
| EV / Net Operating Revenue (X) | 4.57 | 4.93 | 3.87 | 4.56 | 4.14 |
| EV / EBITDA (X) | 30.91 | 37.63 | 30.02 | 29.51 | 36.97 |
| MarketCap / Net Operating Revenue (X) | 4.37 | 4.79 | 3.73 | 4.43 | 3.95 |
| Retention Ratios (%) | 81.10 | 75.99 | 68.84 | 95.86 | 74.53 |
| Price / BV (X) | 11.60 | 13.17 | 10.00 | 11.55 | 9.07 |
| Price / Net Operating Revenue (X) | 4.37 | 4.79 | 3.73 | 4.43 | 3.95 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
After reviewing the key financial ratios for Apollo Hospitals Enterprise Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 100.56. This value is within the healthy range. It has increased from 62.50 (Mar 24) to 100.56, marking an increase of 38.06.
- For Diluted EPS (Rs.), as of Mar 25, the value is 100.56. This value is within the healthy range. It has increased from 62.50 (Mar 24) to 100.56, marking an increase of 38.06.
- For Cash EPS (Rs.), as of Mar 25, the value is 155.05. This value is within the healthy range. It has increased from 111.54 (Mar 24) to 155.05, marking an increase of 43.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 571.09. It has increased from 509.07 (Mar 24) to 571.09, marking an increase of 62.02.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 571.09. It has increased from 509.07 (Mar 24) to 571.09, marking an increase of 62.02.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,515.58. It has increased from 1,325.40 (Mar 24) to 1,515.58, marking an increase of 190.18.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 224.07. This value is within the healthy range. It has increased from 173.64 (Mar 24) to 224.07, marking an increase of 50.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is 171.39. This value is within the healthy range. It has increased from 125.87 (Mar 24) to 171.39, marking an increase of 45.52.
- For PBT / Share (Rs.), as of Mar 25, the value is 139.51. This value is within the healthy range. It has increased from 94.75 (Mar 24) to 139.51, marking an increase of 44.76.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 102.37. This value is within the healthy range. It has increased from 63.77 (Mar 24) to 102.37, marking an increase of 38.60.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 100.55. This value is within the healthy range. It has increased from 62.49 (Mar 24) to 100.55, marking an increase of 38.06.
- For PBDIT Margin (%), as of Mar 25, the value is 14.78. This value is within the healthy range. It has increased from 13.10 (Mar 24) to 14.78, marking an increase of 1.68.
- For PBIT Margin (%), as of Mar 25, the value is 11.30. This value is within the healthy range. It has increased from 9.49 (Mar 24) to 11.30, marking an increase of 1.81.
- For PBT Margin (%), as of Mar 25, the value is 9.20. This value is below the healthy minimum of 10. It has increased from 7.14 (Mar 24) to 9.20, marking an increase of 2.06.
- For Net Profit Margin (%), as of Mar 25, the value is 6.75. This value is within the healthy range. It has increased from 4.81 (Mar 24) to 6.75, marking an increase of 1.94.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.63. This value is below the healthy minimum of 8. It has increased from 4.71 (Mar 24) to 6.63, marking an increase of 1.92.
- For Return on Networth / Equity (%), as of Mar 25, the value is 17.60. This value is within the healthy range. It has increased from 12.95 (Mar 24) to 17.60, marking an increase of 4.65.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.32. This value is within the healthy range. It has increased from 14.97 (Mar 24) to 15.32, marking an increase of 0.35.
- For Return On Assets (%), as of Mar 25, the value is 6.99. This value is within the healthy range. It has increased from 5.36 (Mar 24) to 6.99, marking an increase of 1.63.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.53. This value is within the healthy range. It has increased from 0.32 (Mar 24) to 0.53, marking an increase of 0.21.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 0.64, marking an increase of 0.19.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.17. It has decreased from 1.22 (Mar 24) to 1.17, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 1.13 (Mar 24) to 1.53, marking an increase of 0.40.
- For Quick Ratio (X), as of Mar 25, the value is 1.43. This value is within the healthy range. It has increased from 1.03 (Mar 24) to 1.43, marking an increase of 0.40.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 46.34. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 46.34, marking an increase of 46.34.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 18.89. This value is below the healthy minimum of 20. It has decreased from 24.00 (Mar 24) to 18.89, marking a decrease of 5.11.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 12.39. This value is below the healthy minimum of 20. It has decreased from 13.60 (Mar 24) to 12.39, marking a decrease of 1.21.
- For Earning Retention Ratio (%), as of Mar 25, the value is 81.11. This value exceeds the healthy maximum of 70. It has increased from 76.00 (Mar 24) to 81.11, marking an increase of 5.11.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 87.61. This value exceeds the healthy maximum of 70. It has increased from 86.40 (Mar 24) to 87.61, marking an increase of 1.21.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.03. This value is within the healthy range. It has increased from 5.56 (Mar 24) to 7.03, marking an increase of 1.47.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.21. This value is within the healthy range. It has increased from 3.04 (Mar 24) to 4.21, marking an increase of 1.17.
- For Enterprise Value (Cr.), as of Mar 25, the value is 99,584.27. It has increased from 93,953.52 (Mar 24) to 99,584.27, marking an increase of 5,630.75.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.57. This value exceeds the healthy maximum of 3. It has decreased from 4.93 (Mar 24) to 4.57, marking a decrease of 0.36.
- For EV / EBITDA (X), as of Mar 25, the value is 30.91. This value exceeds the healthy maximum of 15. It has decreased from 37.63 (Mar 24) to 30.91, marking a decrease of 6.72.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.37. This value exceeds the healthy maximum of 3. It has decreased from 4.79 (Mar 24) to 4.37, marking a decrease of 0.42.
- For Retention Ratios (%), as of Mar 25, the value is 81.10. This value exceeds the healthy maximum of 70. It has increased from 75.99 (Mar 24) to 81.10, marking an increase of 5.11.
- For Price / BV (X), as of Mar 25, the value is 11.60. This value exceeds the healthy maximum of 3. It has decreased from 13.17 (Mar 24) to 11.60, marking a decrease of 1.57.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.37. This value exceeds the healthy maximum of 3. It has decreased from 4.79 (Mar 24) to 4.37, marking a decrease of 0.42.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Apollo Hospitals Enterprise Ltd:
- Net Profit Margin: 6.75%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.32% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 17.6% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.21
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.43
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 61.3 (Industry average Stock P/E: 89.84)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.64
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.75%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | No.19, Bishop Gardens, Chennai (Madras) Tamil Nadu 600028 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Prathap C Reddy | Founder & Chairman |
| Mrs. Preetha Reddy | Executive Vice Chairperson |
| Mrs. Suneeta Reddy | Managing Director |
| Mrs. Sangita Reddy | Joint Managing Director |
| Mrs. Shobana Kamineni | Non Exe.Non Ind.Director |
| Mrs. V Kavitha Dutt | Independent Director |
| Dr. Murali Doraiswamy | Independent Director |
| Mrs. Rama Bijapurkar | Independent Director |
| Dr. Som Mittal | Independent Director |
| Mr. M B N Rao | Lead Independent Director |
FAQ
What is the intrinsic value of Apollo Hospitals Enterprise Ltd?
Apollo Hospitals Enterprise Ltd's intrinsic value (as of 19 January 2026) is ₹6268.94 which is 12.11% lower the current market price of ₹7,133.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,02,556 Cr. market cap, FY2025-2026 high/low of ₹8,100/6,001, reserves of ₹9,021 Cr, and liabilities of ₹21,950 Cr.
What is the Market Cap of Apollo Hospitals Enterprise Ltd?
The Market Cap of Apollo Hospitals Enterprise Ltd is 1,02,556 Cr..
What is the current Stock Price of Apollo Hospitals Enterprise Ltd as on 19 January 2026?
The current stock price of Apollo Hospitals Enterprise Ltd as on 19 January 2026 is ₹7,133.
What is the High / Low of Apollo Hospitals Enterprise Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Apollo Hospitals Enterprise Ltd stocks is ₹8,100/6,001.
What is the Stock P/E of Apollo Hospitals Enterprise Ltd?
The Stock P/E of Apollo Hospitals Enterprise Ltd is 61.3.
What is the Book Value of Apollo Hospitals Enterprise Ltd?
The Book Value of Apollo Hospitals Enterprise Ltd is 632.
What is the Dividend Yield of Apollo Hospitals Enterprise Ltd?
The Dividend Yield of Apollo Hospitals Enterprise Ltd is 0.27 %.
What is the ROCE of Apollo Hospitals Enterprise Ltd?
The ROCE of Apollo Hospitals Enterprise Ltd is 16.6 %.
What is the ROE of Apollo Hospitals Enterprise Ltd?
The ROE of Apollo Hospitals Enterprise Ltd is 18.4 %.
What is the Face Value of Apollo Hospitals Enterprise Ltd?
The Face Value of Apollo Hospitals Enterprise Ltd is 5.00.